JPRN-jRCT2080222039已完成1 期
An Open-label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC)
试验速览
- 阶段
- 1 期
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Squamous Non-Small Cell Lung Cancer Disease
- •Clinical Stage IV
- •Measurable or nonmeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
- •No prior chemotherapy regimen, surgery and chest radiotherapy
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322)on-Squamous Non-Small Cell Lung CancerCTIS2022-502010-85-00Merck Healthcare KGaA198
进行中（未招募）
1 期
Assess the Anti-tumor Activity and Safety of Glumetinib in Patient With Advanced c-MET-positive Non-Small Cell Lung CancerAdvance Non-Small Cell Lung CarcinomaLung Cancer, Non-Small Lung Cancer, NSCLC, Met inhibitor, MET exon14 skipping mutationD008175JPRN-jRCT2051200072Hayashi Hidetoshi24
招募中
1 期
M1774 in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322)on-Squamous Non-Small Cell Lung CancerJPRN-jRCT2031230332Ishii Kyoko25
招募中
不适用
A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR)Advanced solid tumors known to overexpress GRPRAdvanced solid tumorsgastrin-releasing peptide receptor10027655NL-OMON54819Advanced Accelerator Applications International SA10
招募中
2 期
NeoRay - Phase I/IIa trial of [177Lu]-NeoB in patients with advanced solid tumors and with [68Ga]-NeoB lesion uptake.2023-507170-41-00Advanced Accelerator Applications International S.A., Advanced Accelerator Applications International S.A.9